We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Presumptive Speaker of the House Rep. Nancy Pelosi (D-Calif.) is promising that the new Democratic leadership will provide the federal government with the authority to directly negotiate with drug companies for lower Medicare costs.
Presumptive Speaker of the House Rep. Nancy Pelosi (D-Calif.) is promising that the new democratic leadership will provide the federal government with the authority to directly negotiate with drug companies for lower Medicare costs.
A class action claim alleging widespread Medicare fraud by the pharmaceutical industry will head to trial today after a federal district court denied an industry motion to dismiss the suit.
Observers on all sides of the dispute over Medicare coverage of certain compounded drugs are anxiously awaiting the Centers for Medicare & Medicaid Services’ (CMS) decision about what factors will be considered in setting reimbursement rates.
Observers on all sides of the dispute over Medicare coverage of certain compounded drugs are anxiously awaiting the Centers for Medicare & Medicaid Services' (CMS) decision about what factors will be considered in setting reimbursement rates.
The FDA approved Genentech’s Avastin as a treatment against the most common kind of lung cancer, after clinical trials showed the drug could increase survival time.
The future of the Centers for Medicare & Medicaid Services’ (CMS) plan to share prescription drug plan data with the FDA in an effort to base Medicare reimbursement on product comparisons is in doubt as the agency determines whether it has the legal authority to share this information, an industry source says.
The future of the Centers for Medicare & Medicaid Services’ (CMS) plan to share prescription drug plan data with the FDA in an effort to base Medicare reimbursement on product comparisons is in doubt as the agency determines whether it has the legal authority to share this information, an industry source says.
HHS’ Office of Inspector General’s (OIG) advisory opinion approving Eli Lilly’s proposed patient assistance program (PAP) should help guide other companies in developing their own programs to supplement the Medicare prescription drug plan, an agency official says.
HHS’ Office of Inspector General’s (OIG) advisory opinion approving Eli Lilly’s proposed patient assistance program (PAP) should help other companies develop their own programs to supplement the Medicare prescription drug plan, an agency official says.